Pharvaris text logo
  • our science
  • our pipeline
  • disease focus: HAE
  • HAE community
  • clinical trials
  • about us
    • about us
    • join us
    • contact
  • investors

Pharvaris to Present Clinical Data of PHA121 for the Treatment of Hereditary Angioedema at the 2021 AAAAI Annual Meeting

by Pharvaris | Feb 1, 2021 | News

Zug, Switzerland, Feb. 1, 2021 – Pharvaris, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of...

Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under Development for the Treatment of Hereditary Angioedema

by Pharvaris | Jan 27, 2021 | News

Data demonstrate the oral bioavailability of PHA121, which was well-tolerated across multiple ascending doses Zug, Switzerland, Jan. 27, 2021 – Pharvaris, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...

Pharvaris Expands Board of Directors with Appointment of David Meeker, M.D., as Chair and Robert Glassman, M.D., as Director

by Pharvaris | Jan 5, 2021 | News

Zug, Switzerland, Jan. 5, 2021 – Pharvaris, a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today...

Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE

by Pharvaris | Nov 18, 2020 | News

New investors include Viking Global Investors, General Atlantic, and Cormorant Asset Management, with an expanded position by Venrock Healthcare Capital Partners Phase 2 study of PHVS416 expected to initiate in 2021 Zug, Switzerland, Nov. 18, 2020 – Pharvaris, a...

Pharvaris Presents Clinical Data at ACAAI 2020 Demonstrating Safety and Therapeutic Potential of Oral PHA121 for the Treatment of HAE

by Pharvaris | Nov 13, 2020 | News

PHA121 outperforms icatibant in a bradykinin-challenge study Zug, Switzerland, Nov. 13, 2020 – Pharvaris, a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema...

Preclinical Characterization of Novel B2-Receptor Antagonists Published in Frontiers in Pharmacology

by Pharvaris | Jul 30, 2020 | News

Data further validate Pharvaris’ B2-receptor-antagonist program Zug, Switzerland, July 30, 2020 – Pharvaris, a clinical-stage company focused on the discovery and development of novel oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and...
« Older Entries

Latest News

  • Pharvaris to Present Clinical Data of PHA121 for the Treatment of Hereditary Angioedema at the 2021 AAAAI Annual Meeting 1st February 2021
  • Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under Development for the Treatment of Hereditary Angioedema 27th January 2021
  • Pharvaris Expands Board of Directors with Appointment of David Meeker, M.D., as Chair and Robert Glassman, M.D., as Director 5th January 2021
  • Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE 18th November 2020
  • Pharvaris Presents Clinical Data at ACAAI 2020 Demonstrating Safety and Therapeutic Potential of Oral PHA121 for the Treatment of HAE 13th November 2020

Categories

  • Board
  • In Memoriam
  • Management & Founders
  • News
  • Publications
  • Scientific Advisors

Privacy    Cookie notice    Terms of Use

Pharvaris 2023 © All rights reserved

contact us